Watching
OPCH · Option Care Health, Inc.
Updated ·
Against its published line
Above its line on the last close.
How to read this
The red mark is the published kill line — the price that would prove the thesis wrong. The dot is where the name closed on 30 October 2026; a dot left of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row reads well clear, with a hollow dot to show the figure is off the drawn scale. Rows run tightest first.
Kill line
A daily close below $29.00, a level that would show the market pricing real risk to the $32.05 cash deal. A second request from federal antitrust regulators, closing guidance moved beyond the first half of 2027, or a failed stockholder vote would also break the case.
Not a pickResearch coverage at low conviction. A medium-or-higher call would open a pick on the scoreboard.
Catalyst (3 days ago)
How picks are graded →The thesis
Option Care Health's shares are pinned to a $32.05-per-share cash takeover by Clayton, Dubilier & Rice (CD&R) and McKesson. The 30 October close of $31.83 sits just below that price, so they are more likely to lag the S&P 500 than lead it over the next three months. The case turns on whether the deal stays on track. The tests are the 4 November 2026 third-quarter results, antitrust clearance and the stockholder vote.
The main new fact since the 22 October note is the preliminary merger proxy, dated 28 October 2026. It spells out the financing, the break fees and an outside date of 5 October 2027. Those terms make the deal harder to abandon. They also make a rival bid less likely. The shares have moved from $31.29 on 21 October to $31.83 on 30 October, so the market is pricing completion as more likely.
The narrative is saturated: the price was set on 6 October 2026, four brokers moved to neutral-equivalent ratings by 9 October 2026, and no broker has acted since. The shares now move only with the odds that the deal closes.
Bullish and bearish views on Option Care Health, Inc.
The bull case on Option Care Health, Inc. (OPCH), in brief: Committed financing behind the cash price. The bear case: Upside is capped at $32.05.
Bull case
- Committed financing behind the cash price. The 28 October 2026 preliminary proxy describes a debt commitment letter dated 5 October 2026 from Goldman Sachs, Bank of America, Barclays, Wells Fargo and Jefferies Finance. It covers up to $3.15 billion in loans and a $500 million revolving credit facility, alongside equity commitments of up to $2,873,295,853 from CD&R Fund XII and McKesson.
- The buyers pay more if they walk. The proxy sets a parent termination fee of $291,927,951, twice the company's $145,963,976 fee. A large reverse fee raises the cost of the buyers walking away.
- A strategic owner with a path to full control. McKesson will invest about $1.4 billion for about 49%, with CD&R holding about 51%, according to McKesson's 6 October 2026 release. The agreement gives McKesson a framework to buy CD&R's stake later.
- Operations were steady before signing. Second-quarter 2026 adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) rose 3.0% to $117.5 million, the company reported on 29 July 2026.
Bear case
- Upside is capped at $32.05. The 30 October close of $31.83 leaves little room to the cash price. Against a rising S&P 500, a fixed payout lags.
- A rival bid is unlikely. The proxy's background section says the buyers refused a go-shop clause, which would have let the company seek other offers after signing. The final agreement has a no-shop clause with a fiduciary out instead. A higher offer would also have to cover the $145,963,976 company termination fee.
- More regulators than antitrust alone. Besides the Hart-Scott-Rodino (HSR) antitrust waiting period, closing requires state healthcare transaction notice reviews, state pharmacy licensure approvals and consents from certain state health regulators, according to the proxy. The outside date of 5 October 2027 leaves room for a long review.
- Thin growth if the deal breaks. Second-quarter 2026 net revenue grew 1.9% to $1,442 million, according to the 29 July 2026 release. Without the premium, the shares would trade on that growth rate again.
- Sell-side support has stepped back. William Blair, Citizens and Barrington Research downgraded the shares to Market Perform on 7 October 2026. UBS cut to Neutral on 9 October 2026 with a $32.05 target, according to Benzinga.
Price setup
The shares closed at $31.83 on 30 October 2026 in split- and dividend-adjusted daily closes. That is 13.0% below the $36.59 52-week high and 34.4% above the level three months earlier. Nearly all of the three-month gain came on the 6 October 2026 deal announcement.
The 14-day relative strength index (RSI) stands at 83.5, a reading usually described as overbought. Benzinga flagged it above 83 on 16 October 2026. For a stock anchored to a cash price, a high RSI mostly shows that the price has been creeping toward the deal price with little day-to-day movement. It does not show speculative buying.
The level that matters is $29.00 on a daily close. A drop that far below the cash price would mean the market sees real risk to the deal. Above it, the price tracks the gap to $32.05 and the time left before closing.
Crowding is limited. No insider sales or share issuance appear in company news since the deal. The 4 November 2026 report is the nearest event. The managed-care and health-services group moved from saturated to maturing in late October. The deal price shields the shares from that cooling unless the deal itself is in doubt.
Catalysts, next 30 days
- Date not disclosed — HSR waiting period. Neither the proxy nor company news gives the HSR filing date. Early expiration would clear the main federal hurdle. A second request, meaning a formal demand from federal regulators for more information, would extend the timeline.
- ~30 June 2027, est. Expected closing. The company guides to the first half of 2027. The outside date in the merger agreement is 5 October 2027.
Elapsed catalysts
- 4 November 2026 — Third-quarter 2026 results, with no live conference call. This is the first operating update since signing. On 29 July 2026 the company guided to low- to mid-single-digit sequential revenue growth for the quarter and full-year net revenue of $5.675 billion to $5.775 billion, then withdrew that guidance on 6 October 2026. A sharp miss against that outlook would test the buyers' commitment. (passed 3d ago)
- Date not yet set — Definitive proxy and special stockholder meeting. The 28 October 2026 preliminary proxy leaves the meeting date blank. Filing the definitive proxy would start the countdown to the vote. (passed 10d ago)
What would change the view
The case breaks if the deal's odds fall. That would show up as a second request from federal antitrust regulators, a state regulator holding up a pharmacy licensure approval, or the company moving expected closing beyond the first half of 2027. A proxy adviser recommending against the deal, or a weak 4 November 2026 report followed by talk of amending the merger agreement, would also break it.
On price, a daily close below $29.00 would show the market pricing real risk to the $32.05 payout.
The rating would rise only if a rival bidder made a public offer above $32.05. The no-shop clause and the company break fee make that unlikely.
What it trades with
While the deal is pending, the shares follow the deal's odds more than their health-services peers Teladoc (TDOC), AMN Healthcare (AMN), ICON (ICLR) and IQVIA (IQV). Their earnings and sector rotation should move Option Care Health little. Credit-market conditions matter more, because the debt package of up to $3.15 billion funds most of the deal. So does any regulatory news on McKesson (MCK), the strategic buyer. In a falling S&P 500 the shares should hold up better than the index, and in a rising one they should lag it.
Notes
- Option Care Health has agreed to be acquired for $32.05 per share in cash by CD&R (about 51%) and McKesson (about 49%); while the deal is pending, the share price is anchored to that figure.
- The company withdrew its financial guidance after signing the merger agreement and is releasing quarterly results without a live conference call.
- The merger agreement gives McKesson a framework to buy CD&R's stake later, subject to conditions and regulatory approvals.
- The merger agreement has a no-shop clause with a fiduciary out, a company termination fee of $145,963,976 and an outside date of 5 October 2027.
Related · shared themes
BTSG
BrightSpring Health Services, Inc.
BrightSpring Health Services is growing profit faster than revenue, as specialty pharmacy margins and acquired home-health branches lifted…
HUM
Humana Inc.
Humana's 2027 Star Ratings put 95% of its Medicare Advantage members in 4-star-or-better plans, restoring 2028 bonus revenue; Humana's 6…
MCK
McKesson Corporation
McKesson's earnings keep beating its own guidance, lifting fiscal 2027 adjusted EPS guidance to $45.60–$46.40 on 4 November 2026; the…
ARDT
Ardent Health, Inc.
Ardent Health's cost-led hospital turnaround is running ahead of plan, with 2026 adjusted EBITDA guidance raised to $500–$535 million; the…
See also · stocks to watch